The ratio of associated peptide to vitamin B12 has varied slightly in the different complexes but has never exceeded 7.1 to 1.
The doses of the different batches of the peptide complexes are given in terms of cobalamin content alone, as estimated spectrophotometrically at 550 mix.
The results are summarized in Table I . Thirty-two of the patients are females and 18 are males. Their ages range from 39 to 84 years (average 62). Eight patients have left the district and are now lost to survey (see Table I ). All these were in complete health when last seen.
A further nine patients died during the period under review, but in no case was death associated with pernicious anaemia either directly or indirectly. The average age at the time of death was 73.
The average daily maintenance dose of all 50 cases was 19.5
ug. of vitamin Bl2, and 39 (78%) of them have been kept in health throughout on the original maintenance dose; in the remaining 11 (22%) cases an increase was made to the initial dose. Ten (20%) cases in the series developed iron deficiency, three developed mild neuropathic symptoms, and one developed an associated folic-acid deficiency. Those patients who in any way required an alteration in treatment during the period of survey are described in greater detail. Neuropathy Three patients (Cases 9, 18, and 22) developed neuropathy. Pernicious Anaemia-Mooney and Heathcote this time were associated with a weakness of the hands which prevented the patient from gripping objects securely. Co-ordinated movements of the hands-for example, shaving-were also affected. 
Increase in Maintenance Dose
Apart from the increases required in the three neurological cases mentioned above, it became necessary also to augment the initial maintenance dosage of a further eight cases (Table II) . (1,000 pg.) was therefore given, but three days later the Hb had dropped further to 42% and the P.C.V. to 18%,', and no reticulocyte response was detectable. From the 212th day onwards 45 mg. of folic acid was given daily by mouth, in addition to 300 ,og. of vitamin-BJ--peptide. A brisk reticulocyte response resulted (maximum 22% on 217th day), and on the 219th day the haemoglobin had risen to 50% and the P.C.V. to 25%. The dosage of folic acid and vitamin-B,2--peptide was then gradually reduced until, by the 279th day, the daily maintenance dosage was S mg. of folic acid and 10 pug. of vitamin-BjI-peptide. This dosage has remained unchanged up to the present (1,500th day). Currently the Hb is 97%, the P.C.V. 40%, and serum vitamin-B12 level 96 /4opg./ml.
Discussion Serum Vitamin-B12 Levels
The efficacy of our preparations has in the past been challenged because the serum vitamin-B12 levels have tended to remain lower than normal on this form of therapy, when the patient has received daily doses of less than 100 ftg. (equivalent) of vitamin B12 (Varadi, 1959; Varadi and Elwis, 1960 Shinton, 1960; Smith, 1961) . These criticisms were largely based on the widespread but unproved assumption that serum vitamin-B12 levels reflect the degree of tissue saturation on vitamin-B12 therapy under all circumstances. Indeed, one of the critics (Varadi, 1959 (Varadi, , 1960 actually classified a case as "relapsed" merely because the serum vitamin-B level fell when the daily dosage was reduced from 300 to 100 1,g. of vitamin-B12-peptide, though the blood picture did not deteriorate.
We have already shown, however, that if such an assumption were true it would also have to be conceded that the perniciousanaemia patient is capable of absorbing several times more vitamin B12 from the gut than does the normal average individual (Mooney and Heathcote, 1961b) . Furthermore, vitamin B, 2 is essentially an intracellular substance and is clearly not di tributed in equal proportions between the body compartments. Thus, although the plasma makes up some 5 % of the total body fluid, its own vitamin-B12 content is lcss than 0 .05',z, of the total amount found in the body. It would be more than optimistic, therefore, to assume that variations in this tiny amount in the plasma would necessarily, and in all circumstances, follow accurately the changes in the remaining 99.9% residing in the liver and other tissues. Whatever the practical significance, if any, of the serum vitamin-B12 levels on vitamin-B12-peptide therapy, it is now clear from the evidence presented in Table I that low serum vitamin-B12 levels are quite consistent with complete health for long periods on vitamin-B12-peptide. Furthermore, in the three cases which developed neuropathy the onset was not preceded by a fall, nor was the clinical recovery accompanied by a significant rise, in the level of vitamin B12 in the serum. In this connexion it is pertinent to recall the work of Banerjee and Chatterjea (1960) , who have shown that low levels of serum vitamin B12, are quite consistent with good health in normal individuals on natural low-protein diets.
Comparison with Crystalline Vitamin B,2
The effect of oral crystalline vitamin B12 in pernicious anaemia has been studied extensively, and most of the work on this subject has been reviewed by Ungley (1952) , by Brody et al. (1959) , or by ourselves Mooney, 1958a, 1958b) . The differing schemes of dosage employed in the studies make it difficult to summarize the findings in precise terms, but there appears to be fairly general agreement that dosages of at least 100 jug. are required in most cases, and some patients may require more. In fact Britton (1963) 80 ,ug. daily is the solitary example of partial refractoriness. These results, supported by the control experiments recorded in our earlier work Heathcote, 1960, 1961a) , demonstrate that the vitamin-B12-peptide complexes are much more effective than crystalline vitamin B 2 alone in the oral treatment of pernicious anaemia.
Refractoriness
This has been constantly observed in cases of pernicious anaemia treated with all so-called purified intrinsic-factor preparations (Meulengracht, 1953 ; Blackburn et al., 1955; N0rregaard, 1955 ; Bastrup-Madsen, 1957; Schwartz et al., 1957 Schwartz et al., , 1958 . Signs of refractoriness usually appear within 12 months and affect over half of all cases (Schwartz et al., 1958) . However, in our series of 50 patients, who have been treated exclusively with vitamin-B12-peptide complexes for an average period of over three and a half years, only one case of partial refractoriness developed. This patient (Case 24) underwent a sudden deterioration after approximately six months' treatment, and this could be overcome only by increasing the dosage of vitamin-BI2-peptide from 10 to 80 jug. daily. On this higher dosage, however, a satisfactory blood picture was achieved and maintained until her death from cerebral haemorrhage over a year later.
Aetiology of Pernicious Anaemia
Although some 1,300 papers have now been written on " intrinsic factor" (for review see Glass, 1963) , little is known about it except that it is alleged to be some form of protein which is capable of binding with vitamin B12-a property shared by other proteins. We believe that the reason why intrinsic factor has not yet been isolated is simply that it does not exist. Indeed, the theory upon which is depends (Castle, 1953) relies on two false assumptions.
The first assumption-that crystalline vitamin B12 exists as such in animal protein-is no longer seriously defended, and for some years now it has been widely conceded that it is almost invariably attached to proteinaceous material in its natural form. The second assumption-that the large molecule of vitamin B12 has to combine with another much larger molecule before it can be absorbed-defies all known principles of protein digestion.
In exact opposition to the view that vitamin B12 has to be attached to a protein molecule (intrinsic factor) before absorption, we believe that the vitamin has to be detached to a greater or less degree from associated protein before absorption can take place. We believe that the essential step in this detachment is achieved by a specific gastric endopeptidase, deficiency of which results in the development of pernicious anaemia, and have suggested that this enzyme should be called " cobalamase" (Heathcote and Mooney, 1962 ).
In conclusion, we believe that vitamin-B,,-peptide complexes are effective in the oral treatment of pernicious anaemia simply because they resemble more closely the final form in which the vitamin is absorbed.
Summary
Fifty cases of uncomplicated pernicious anaemia have been treated with oral vitamin-B12-peptides for periods ranging from one to seven years. The average daily dose was 19 /jg. (vitamin-B12 equivalent) We believe that pernicious anaemia is caused by the lack of a specific gastric peptidase (cobalamase) which initiates the digestion of the protein at or about the site of attachment of the vitamin-BI2 molecule, and that the vitamin-B12-peptide complexes are effective because they simulate to a greater, or less, degree the final form in which the vitamin is absorbed.
